Work

Grappling Covishield fear in India: the urgent need for strong countermeasures to build vaccine confidence

Year: 2024

Type: article

Abstract: The Oxford/AstraZeneca COVID-19 vaccine (ChAdOx1 nCoV-19), a chimpanzee adenovirus-vectored non-replicating recombinant vaccine, has significantly managed COVID-19 globally. Of the 13 billion COVID-19 vaccine doses administered, ChAdOx1 nCoV-19 is the most widely used, reaching 180 countries and saving over six billion lives.1 The Serum Institute of India (SII) was pivotal in producing and distributing this vaccine, branded as Covishield, which was crucial in India’s contribution to the COVAX initiative, supplying vaccines to over 96 nations and UN agencies.

Source: The Lancet Regional Health - Southeast Asia

DOI: 10.1016/j.lansea.2024.100447

Authors: Abhijit Poddar, S.R. Rao

Institution: Sri Balaji Vidyapeeth University

Language: English

Topic: Vaccine Coverage and Hesitancy

Subfield: Health

Field: Social Sciences

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,000